Formosa strikes exclusive deal with Arrotex to launch eye surgery drug in Australia & NZ
The innovative eyedrop targets inflammation and pain following ocular surgery
The innovative eyedrop targets inflammation and pain following ocular surgery
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
Under the deal, Quiver will receive an undisclosed advance payment and research support
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen
Subscribe To Our Newsletter & Stay Updated